Senate bill aims to rebuild drug manufacturing infrastructure: 3 notes

Becker’s Hospital Review – Tuesday, June 17, 2025
By Alexandra Murphy

A bipartisan group of U.S. senators has reintroduced a bill designed to address ongoing shortages of generic drugs by expanding domestic stockpiles and manufacturing capacity.

Here are three notes:

1. The Rolling Active Pharmaceutical Ingredient and Drug Reserve Act, reintroduced by Sens. Gary Peters, D-Mich., Marsha Blackburn, R-Tenn., Tim Kaine, D-Va., and Ted Budd, R-N.C., would require HHS to award contracts to manufacturers in the U.S. or allies to maintain stockpiles of essential medications and ingredients, according to a June 12 news release from Mr. Peters’ office.
2. A 2023 report cited in the release showed that at least 15 medications remained in shortage for more than a decade, with many generics being low-cost but complex to manufacture.
3. In addition to expanding the federal drug stockpile, the senators also requested the Government Accountability Office investigate unused domestic manufacturing and federal efforts to scale up advanced production.

Access this article at its original source.